List of Tables
Table 1. Neurodegenerative Diseases Drug Market Trends
Table 2. Neurodegenerative Diseases Drug Market Drivers & Opportunity
Table 3. Neurodegenerative Diseases Drug Market Challenges
Table 4. Neurodegenerative Diseases Drug Market Restraints
Table 5. Global Neurodegenerative Diseases Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Neurodegenerative Diseases Drug Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Neurodegenerative Diseases Drug Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Neurodegenerative Diseases Drug Product Type
Table 9. Key Companies Time to Begin Mass Production of Neurodegenerative Diseases Drug
Table 10. Global Neurodegenerative Diseases Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Neurodegenerative Diseases Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Neurodegenerative Diseases Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Neurodegenerative Diseases Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Neurodegenerative Diseases Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Neurodegenerative Diseases Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Neurodegenerative Diseases Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Neurodegenerative Diseases Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Neurodegenerative Diseases Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Neurodegenerative Diseases Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Neurodegenerative Diseases Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Neurodegenerative Diseases Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Neurodegenerative Diseases Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Neurodegenerative Diseases Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Neurodegenerative Diseases Drug Sales Value by Region (2019-2024) & (%)
Table 27. Global Neurodegenerative Diseases Drug Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Neurodegenerative Diseases Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Neurodegenerative Diseases Drug Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Neurodegenerative Diseases Drug Sales Value, (2025-2030) & (US$ Million)
Table 31. Biogen Basic Information List
Table 32. Biogen Description and Business Overview
Table 33. Biogen Neurodegenerative Diseases Drug Products, Services and Solutions
Table 34. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Biogen (2019-2024)
Table 35. Biogen Recent Developments
Table 36. Pfizer Basic Information List
Table 37. Pfizer Description and Business Overview
Table 38. Pfizer Neurodegenerative Diseases Drug Products, Services and Solutions
Table 39. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Pfizer (2019-2024)
Table 40. Pfizer Recent Developments
Table 41. Roche Basic Information List
Table 42. Roche Description and Business Overview
Table 43. Roche Neurodegenerative Diseases Drug Products, Services and Solutions
Table 44. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Roche (2019-2024)
Table 45. Roche Recent Developments
Table 46. Novartis Basic Information List
Table 47. Novartis Description and Business Overview
Table 48. Novartis Neurodegenerative Diseases Drug Products, Services and Solutions
Table 49. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Novartis (2019-2024)
Table 50. Novartis Recent Developments
Table 51. Sanofi Basic Information List
Table 52. Sanofi Description and Business Overview
Table 53. Sanofi Neurodegenerative Diseases Drug Products, Services and Solutions
Table 54. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Sanofi (2019-2024)
Table 55. Sanofi Recent Developments
Table 56. Teva Pharmaceuticals Basic Information List
Table 57. Teva Pharmaceuticals Description and Business Overview
Table 58. Teva Pharmaceuticals Neurodegenerative Diseases Drug Products, Services and Solutions
Table 59. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Teva Pharmaceuticals (2019-2024)
Table 60. Teva Pharmaceuticals Recent Developments
Table 61. Orion Pharma Ltd Basic Information List
Table 62. Orion Pharma Ltd Description and Business Overview
Table 63. Orion Pharma Ltd Neurodegenerative Diseases Drug Products, Services and Solutions
Table 64. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Orion Pharma Ltd (2019-2024)
Table 65. Orion Pharma Ltd Recent Developments
Table 66. UCB S.A Basic Information List
Table 67. UCB S.A Description and Business Overview
Table 68. UCB S.A Neurodegenerative Diseases Drug Products, Services and Solutions
Table 69. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of UCB S.A (2019-2024)
Table 70. UCB S.A Recent Developments
Table 71. ACADIA Pharmaceuticals Inc. Basic Information List
Table 72. ACADIA Pharmaceuticals Inc. Description and Business Overview
Table 73. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Products, Services and Solutions
Table 74. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of ACADIA Pharmaceuticals Inc. (2019-2024)
Table 75. ACADIA Pharmaceuticals Inc. Recent Developments
Table 76. Lundbeck Pharmaceuticals Italy S.p.A. Basic Information List
Table 77. Lundbeck Pharmaceuticals Italy S.p.A. Description and Business Overview
Table 78. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Products, Services and Solutions
Table 79. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Lundbeck Pharmaceuticals Italy S.p.A. (2019-2024)
Table 80. Lundbeck Pharmaceuticals Italy S.p.A. Recent Developments
Table 81. Mitsubishi Tanabe Pharma America Basic Information List
Table 82. Mitsubishi Tanabe Pharma America Description and Business Overview
Table 83. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Products, Services and Solutions
Table 84. Revenue (US$ Million) in Neurodegenerative Diseases Drug Business of Mitsubishi Tanabe Pharma America (2019-2024)
Table 85. Mitsubishi Tanabe Pharma America Recent Developments
Table 86. Key Raw Materials Lists
Table 87. Raw Materials Key Suppliers Lists
Table 88. Neurodegenerative Diseases Drug Downstream Customers
Table 89. Neurodegenerative Diseases Drug Distributors List
Table 90. Research Programs/Design for This Report
Table 91. Key Data Information from Secondary Sources
Table 92. Key Data Information from Primary Sources
Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Neurodegenerative Diseases Drug Product Picture
Figure 2. Global Neurodegenerative Diseases Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Neurodegenerative Diseases Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Neurodegenerative Diseases Drug Report Years Considered
Figure 5. Global Neurodegenerative Diseases Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Neurodegenerative Diseases Drug Revenue in 2023
Figure 7. Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Immunomodulator Picture
Figure 9. Interferons Picture
Figure 10. Decarboxylase Inhibitors Picture
Figure 11. Dopamine Agonists Picture
Figure 12. Others Picture
Figure 13. Global Neurodegenerative Diseases Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Neurodegenerative Diseases Drug Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Multiple Sclerosis
Figure 16. Product Picture of Parkinson’s Disease
Figure 17. Product Picture of Alzheimer’s Disease
Figure 18. Product Picture of Spinal Muscular Atrophy (SMA)
Figure 19. Product Picture of Others
Figure 20. Global Neurodegenerative Diseases Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Neurodegenerative Diseases Drug Sales Value Market Share by Application, 2023 & 2030
Figure 22. North America Neurodegenerative Diseases Drug Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Neurodegenerative Diseases Drug Sales Value by Country (%), 2023 VS 2030
Figure 24. Europe Neurodegenerative Diseases Drug Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Neurodegenerative Diseases Drug Sales Value by Country (%), 2023 VS 2030
Figure 26. Asia Pacific Neurodegenerative Diseases Drug Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia Pacific Neurodegenerative Diseases Drug Sales Value by Country (%), 2023 VS 2030
Figure 28. South America Neurodegenerative Diseases Drug Sales Value (2019-2030) & (US$ Million)
Figure 29. South America Neurodegenerative Diseases Drug Sales Value by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Neurodegenerative Diseases Drug Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Neurodegenerative Diseases Drug Sales Value by Country (%), 2023 VS 2030
Figure 32. Key Countries/Regions Neurodegenerative Diseases Drug Sales Value (%), (2019-2030)
Figure 33. United States Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 34. United States Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 35. United States Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 36. Europe Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 37. Europe Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 38. Europe Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 39. China Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 40. China Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 41. China Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 42. Japan Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 43. Japan Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 44. Japan Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 45. South Korea Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 46. South Korea Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 47. South Korea Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 48. Southeast Asia Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 49. Southeast Asia Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 50. Southeast Asia Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 51. India Neurodegenerative Diseases Drug Sales Value, (2019-2030) & (US$ Million)
Figure 52. India Neurodegenerative Diseases Drug Sales Value by Type (%), 2023 VS 2030
Figure 53. India Neurodegenerative Diseases Drug Sales Value by Application (%), 2023 VS 2030
Figure 54. Neurodegenerative Diseases Drug Industrial Chain
Figure 55. Neurodegenerative Diseases Drug Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
